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Abstract
Introduction
Behavioral Activation is a behavioral-based treatment that has been proposed as suitable
for smoking cessation, as it simultaneously addresses reinforcement-related variables and
also moodmanagement. The aim of this study was to compare the effects of a cognitive-
behavioral smoking cessation treatment with components of behavioral activation
(SCBSCT-BA) with a standard cognitive-behavioral treatment (SCBSCT), and a wait-list
control group (WL).
Method
The sample was comprised of 275 adults smokers (61.4% females, mean age = 45.36, SD
= 10.96). After baseline assessment sessions, participants were randomized (ratio: 2.2.1.)
to SCBSCT-BA, SCBSCT, or WL. Active groups received 8 weekly 1-hour face-to-face
group sessions. Biochemically verified smoking abstinence and depressive symptoms were
assessed at the end of treatment, and at 3-, 6-, and 12-month follow-ups.
Results
Significant treatment effects in 7-dayspoint prevalence abstinence rates were found for both
active groups at the end of treatment. Abstinence rates at 12-months follow-up were 30%
for SCBSCT-BA, and 18% for SCBSCT. Using Multiple Imputation for missing data, regres-
sion analysis showed significantly greater ORs for the SCBSCT-BA condition (vs. SCBSCT)
at the end of treatment and at 3-months follow-up. At 6-, and 12-months follow-ups, ORs for
the SCBSCT-BA condition, although greater, did not reach statistical significance. Multilevel
analysis showed that abstinence was related to reductions in depressive symptoms.
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Conclusions
SCBSCT-BA obtained positive results at short andmedium term. Participants who quit
smoking experienced a significant reduction in depressive symptoms. Findings support the
benefit of adding BA to a cognitive-behavioral smoking cessation treatment.
Trial registration
www.clinicaltrials.gov NCT02844595.
Introduction
Smoking cessation treatments have shown to significantly aid in the achievement of tobacco
abstinence [1]. Despite the evidence of the efficacy of such treatments to quit smoking, in
recent years, a reduction in abstinence rates has been observed [2–4]. Previous work suggests
that this phenomenon could be due to a change in treatment-seeking smokers. For example,
smokers of recent cohorts show significantly greater self-reported depressive symptoms when
compared to prior studies [2,4]. Research had consistently shown that depressive symptoms
and negative affect are highly associated with smoking behavior [5], and with difficulties in
quit smoking and maintain abstinence [6–8].
Quitting smoking is a complex process that involves psychological, physiological, and envi-
ronmental variables. Reinforcement processes, for example, are relevant factors implicated in
substance use onset and maintenance [9]. In the case of cigarette smoking, positive reinforce-
ment acts through nicotine and non-nicotine effects, providing pleasure by smoking itself
and/or enhancing the reward value of activities or stimuli associated with smoking [10].
Another important mechanism implied in smoking maintenance is negative reinforcement.
This process assumes the use of smoking as a way of avoiding nicotine withdrawal symptoms,
and also as a way to manage negative affect or as a strategy to avoid and/or escape from psy-
chological distress in general [11]. Moreover, behavioral approaches have suggested that a low
natural positive reinforcement in the environment is implicated in the onset and maintenance
of smoking behavior, through the lack of rewarding smoking-free stimuli and/or activities
[12]. Lastly, studies have shown that the interest, pleasure, and enjoyment of nonsmoking-
related activities can be reduced during the smoking cessation process [13].
Because in depression a diminished exposure to positive rewarding activities or the pres-
ence of dysfunctional patterns of behavioral avoidance is also common [14,15], reinforce-
ment-related factors would be especially relevant for smokers with depressive symptoms. For
instance, previous research has pointed out that smokers with depressive symptoms perceive
more benefits and reward value of cigarettes than of alternative rewards when compared to
non-depressed smokers [16], and depression-prone smokers have strong expectations and
beliefs about the reduction of negative affect and the increase of positive affect through smok-
ing [17]. These variables also have an impact on smoking cessation outcomes. Several studies
indicate that depression-prone smokers experience an increase in negative affect and a reduc-
tion in positive affect when they try to quit smoking, leading to a higher probability of cessa-
tion failure or relapse [18].
Due to the prevalence of depressive symptoms is clearly higher among smokers than
among those who have never smoked or quit smoking [19], development of smoking cessation
treatments that take into account such symptomatology is needed. In fact, previous research
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has found that specific treatments adding behavioral mood management components to stan-
dard smoking cessation treatments increase abstinence rates [8]. Nevertheless, a recent system-
atic review assessing the effectiveness of smoking cessation treatments in smokers with major
depression or depressive symptoms found that the studies conducted to date are insufficient to
establish a clear conclusion about the effectiveness of such treatments [20]. Consequently, the
authors highlight the need of further research addressing issues of the previous studies, such
as, sample sizes, heterogeneity of targeted populations, or the presence of other comorbid con-
ditions. In addition, while there exist numerous studies examining the efficacy of pharmaco-
logical (nicotine replacement therapy, bupropion or varenicline) and combined
(pharmacological + behavior therapy or counseling) interventions, research into exclusively
cognitive-behavior interventions to quit smoking taking into account depressive symptoms, is
still scarce [21].
Literature examining the implication of reinforcement factors on smoking and the relation
with depressive symptoms has led to an interest in the development and assessment of smok-
ing cessation treatments addressing reinforcement-related variables, negative mood manage-
ment, and positive affect promotion by increasing access to rewarding stimuli alternative to
cigarettes, and engagement in nonsmoking-related reinforcing and pleasant activities [22].
Behavioral Activation (BA) is a treatment that includes components based on this behavioral
approach. This approach could be suitable for smoking cessation, as it simultaneously
addresses depressive symptoms and the above-mentioned reinforcement-related variables. BA
can be defined as a behavioral-based treatment that follows the principles of operant condi-
tioning in order to promote rewarding experiences, reducing behavioral avoidance patterns
and increasing engagement in positively reinforced activities [23].
BA has shown its efficacy and cost-effectiveness, resulting in a front-line treatment for
depression [24,25]. In addition, it is also an empirically supported treatment to increase well-
being in nonclinical populations [26], and it has obtained positive results when it was included
in the treatment of substance use disorders [27–29].
Although BA integrated in smoking cessation treatment has shown preliminary efficacy for
improving smoking cessation outcomes and depressive symptoms [30–32], some methodolog-
ical issues such as sample size or short-term follow-ups prevent clearly confirming its effective-
ness. In order to overcome this gap, the current study was designed to evaluate the potential
benefit of adding BA components to a cognitive-behavioral smoking cessation treatment.
Additionally, most studies address smoking cessation in samples including participants with
or without depression separately. As research has confirmed that even very low levels of
depressive symptomatology can impact smoking cessation outcomes [33], we did not exclude
participants on the basis of their depressive symptoms.
To our knowledge, this study is the largest randomized clinical trial in terms of sample size
to evaluate the long-term effects of a BA-based treatment for smoking cessation. This trial was
designed to compare a Standard Cognitive-Behavioral Smoking Cessation Treatment plus BA
(SCBSCT-BA) to two control conditions, a Standard Cognitive-Behavioral Smoking Cessation
Treatment (SCBSCT) condition that matched SCBSCT-BA in treatment contact time, and a
Wait-List (WL) condition. This three-arm design allows comparisons between both active
groups in order to determine the differential effect of BA, and also comparisons of both active
groups to the WL condition, which can serve as a benchmark for assessing the benefits of treat-
ment conditions, and it can provide control over the effects of repeated assessment and the
expectancy of receiving treatment.
Therefore, our main objective was to assess the effects of SCBSCT-BA, in terms of smoking
abstinence rates and improvement of depressive symptoms, at the end of treatment, and at 3-,
6-, and 12-month follow-ups. Our hypotheses were as follows: (a) individuals randomized to
PLOSONE | https://doi.org/10.1371/journal.pone.0214252 April 8, 2019 3 / 20
the two active conditions (SCBSCT-BA and SCBSCT) would be more likely to achieve absti-
nence and to reduce depressive symptoms at the end of treatment than those randomized to
the WL condition; (b) individuals randomized to SCBSCT-BA would be more likely to achieve
and maintain abstinence at the end of treatment, and at the 3-, 6-, and 12-month follow-ups
(vs. SCBSCT) and; (c) individuals randomized to SCBSCT-BA would be more likely to reduce
their depressive symptoms at the end of treatment, and at the 3-, 6-, and 12-month follow-ups
(vs. SCBSCT).
Materials andmethods
Setting
This study was conducted at the Smoking Cessation and Addictive Disorders Unit of the Uni-
versity of Santiago de Compostela (Spain) between January 2016 and April 2018. The Bioethics
Committee of the University of Santiago de Compostela approved the study, which is regis-
tered with the international standard randomized controlled trial number NCT02844595
(www.clinicaltrials.gov).
Study design and randomization
A three-arm, single blind, randomized controlled design was used to assess the efficacy of a
cognitive-behavioral treatment with BA components to quit smoking. Randomization was
conducted according to a computer-generated allocation sequence (ratio: 2.2.1.) to the experi-
mental group (SCBSCT-BA), active comparator group (SCBSCT), or wait-list control group
(WL). Randomization was not stratified, but it was conducted through blocks of 5 and 10 par-
ticipants in order to balance enrollment across conditions during the recruitment period.
Researchers conducting assessments were blind to group allocation, which occurred subse-
quently. Due to the nature of the study, participants were aware that they were assigned to one
of the three arms. Nevertheless, participants were not informed about the details of treatment
components, and they did not know the research question or the study objectives. After alloca-
tion, both active treatments were administered in eight weekly 60-minute sessions. Sessions
were performed in groups of 6–8 participants. Post-treatment assessments were carried out
during Session 8 (end of treatment), and after these, face-to-face follow-ups were conducted at
3, 6, and 12 months.
The software used for sample size calculation was G�Power3 Software [34]. The sample size
was calculated to detect a 20% difference between the two active groups in the proportion of
individuals with biochemically confirmed abstinence at the end of treatment (80% power at a
two-tailed alpha of .05). A minimum of 102 participants per active group was required. The
sample size of the WL control group was set for a minimum of 51 participants. This unbal-
anced design was chosen because larger abstinence rates were expected in both active groups
as compared to the WL.
Participant recruitment
Participants were recruited through the media, posters in healthcare centers, word of mouth,
or referred to the unit by primary care physicians or other specialized services of the public
healthcare system. Before participants were enrolled in the study, written informed consent
for participation was obtained. No economic compensation for participating in the study was
provided.
Sample selection was carried out according to the following inclusion criteria: aged 18 or
over; wishing to participate in the treatment program; providing written informed consent;
PLOSONE | https://doi.org/10.1371/journal.pone.0214252 April 8, 2019 4 / 20
and smoking at least 8 cigarettes per day. Exclusion criteria were: a diagnosis of severe mental
disorder (bipolar disorder and/or psychotic disorder); concurrent substance use disorder
(alcohol, cannabis, stimulant, hallucinogen and/or opioid); having participated in the same or
similar treatment during the previous year or having received pharmacological smoking cessa-
tion treatment (nicotine replacement therapy, bupropion, or varenicline) during the previous
year; presence of a high life-risk pathology that would require immediate individual treatment
(i.e., recent myocardial infarction); and smoking tobacco products other than cigarettes (i.e.,
cigars, electronic devices). The overall participant’s flow chart is reported in Fig 1.
Assessment
Two baseline assessment sessions were carried out. During the first assessment session, socio-
demographic characteristics, smoking-related and depression-related variables were collected
through a face-to-face structured interview. We also applied the following instruments:
Fig 1. Consort flow chart. Consolidated standards of reporting trials diagram for patient allocation. The randomization ratio was 2.2.1.
https://doi.org/10.1371/journal.pone.0214252.g001
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Smoking Habit Questionnaire [35]. It consists of 56 items designed to gather informa-
tion both on sociodemographic variables (sex, age, marital status, educational level) and
tobacco use.
Fagerstro¨m Test for Cigarette Dependence (FTCD) [36–38]. It is made up of six items
for the assessment of cigarette dependence. The Spanish version has a Cronbach alpha of .65.
Beck Depression Inventory II (BDI-II) [39,40]. This is a 21-item self-report scale mea-
suring current depressive symptoms. The Spanish version has a Cronbach alpha of .90.
Environmental Reward Observation Scale (EROS) [41,42]. This is a 10-item self-report
measure examining the amount and availability of environmental reward. The Spanish version
has a Cronbach’s alpha of .86.
Behavioral Activation for Depression Scale (BADS) [43,44]. This 25-item questionnaire
was designed to measure the degree to which a person engages in activities. The Spanish ver-
sion has a Cronbach’s alpha of .90.
Client Satisfaction Questionnaire (CSQ-8) [45,46]. This 8-item instrument measure
general satisfaction with treatment services. The general score is used organized according to 3
levels of satisfaction: 1) low (8–20); 2) medium (21–26); and 3) high (27–32).
Assessment of carbon monoxide (CO) in expired air. This measure was conducted
through the use of the Micro+ Smokerlyzer (Bedfont Scientific Ltd, Maidstone, Kent, UK). CO
was assessed at baseline, at the end of treatment, and at the 3-, 6-, and 12-month follow-ups to
corroborate self-reported abstinence.
End of treatment and follow-up questionnaires. During last intervention session (ses-
sion 8), participants filled in an End of Treatment (EOT) questionnaire [47]. After that, face-
to-face follow-ups at 3, 6, and 12 months post-treatment were carried out, at which time par-
ticipants filled in the corresponding questionnaire.
Conditions
A full description of the protocol and session-by-session treatment components has been pub-
lished [48]. Treatment conditions were exclusively cognitive-behavioral-based interventions,
and pharmacotherapy was not used. Both active conditions consisted of 8 weekly 1-hour face-
to-face group sessions. Quit day was scheduled between sessions 5 and 6 of both active
conditions.
Standard cognitive-behavioral smoking cessation treatment (SCBST). It consists of a
multicomponent cognitive-behavioral manualized treatment to quit smoking, called “Pro-
grama para Dejar de Fumar” (Smoking Cessation Program [49]). Originally, SCBST is applied
in 6 sessions, but the number of sessions was extended to 8 in order to allow a time-matched
comparator condition. Its components are smoking self-report, information about tobacco,
nicotine fading, stimulus control, activities to prevent withdrawal syndrome, physiological
feedback on cigarette consumption through CO in expired air, and relapse-prevention strate-
gies (assertion training, problem-solving training, changing tobacco-related misconceptions,
management of anxiety and anger, exercise, and weight control).
Standard cognitive-behavioral smoking cessation treatment plus BA (SCBST-BA). BA
was applied along with the previously described standard cognitive-behavioral smoking cessa-
tion treatment. The amount of time used for the components applied in the standard condi-
tions was readjusted to allow the incorporation of BA procedures. In addition to the
mentioned treatment elements, it included: analysis of the relationship between behavior and
mood, identification of situations and behaviors that worsen mood, identification of avoidance
behaviors and rumination, self-report of pleasant daily activities, and pleasant activity schedul-
ing to increase engagement in non-smoking-related rewarding activities.
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Wait list (WL). This was a delayed-treatment control group for a period of 3 months, dur-
ing which participants did not receive any treatment. Three months after the assessment ses-
sions, another assessment session was carried out, after which participants were offered to
participate in a smoking cessation treatment.
Treatment delivery
Two trained therapists (Master level in Counseling Psychology) with years of experience in the
application of the SCBSCT conducted the group treatment sessions. One of the therapists was
trained in BA procedures (50 hours supervised by a clinical psychologist) and conducted the
CBSCT-BA sessions. In previous studies conducted by our group, therapists’ effect on the
application of the SCBSCT was analyzed, finding no significant differences in abstinence rates
between therapists[50].
Sessions were video-recorded in order to supervise the study protocol procedures and also
adherence to protocol. Supervision was conducted independently by two clinical psycholo-
gists, who also provided feedback to the therapists. As mentioned before, both treatments were
manualized, including a detailed session-by-session protocol and follow-up procedures.
Outcomes
Primary outcomes. The smoking-related primary outcome was point-prevalence absti-
nence defined according to Russell Standard (RS) criteria [51]. Participants were considered
abstinent if they reported abstinence, not even a puff of a cigarette, for� 7 days at the end of
treatment, 3-, 6- and 12-month follow-ups, and had an expired CO reading of� 9 parts per
million (ppm) [52]. Participants were considered smokers when they reported to be abstinent
but had a CO reading of� 10 ppm, or reported being smokers during the face-to-face follow-
up session or by telephone.
The depression-related primary outcome was the longitudinal examination of depressive
symptoms, assessed through the BDI-II, in each active group.
Secondary outcomes. We examined whether there was a reduction of cigarette consump-
tion over time in those participants smoking at the 12-month follow-up, comparing treatment
conditions. We also analyzed the effect size of depressive symptoms change, assessed through
the BDI-II, behavioral activation, assessed through BADS, and environmental reward, assessed
through EROS, from baseline to the 12-month follow-up, in each condition. Finally, we exam-
ined the session’s attendance in each condition and its mediation role in abstinence outcomes.
Statistical analysis
Chi-square tests and one-way ANOVA tests were used to evaluate differences between
CBSCT, CBSCT-BA, and WL groups on demographics, smoking-related and depression-
related variables. To account for multiple testing, we applied the Bonferroni-adjusted signifi-
cance level for the chi-square test. To determine effect sizes, we used Cramer’s V, Cohen’s d,
and partial eta-square (ηp
2).
Analyses were conducted using intention-to-treat, which includes in the primary analysis
all participants who were randomized. In order to handle missing data about primary out-
comes (smoking status), we used Multiple Imputation (MI) [53,54]. We imputed missing data
with the expectation-maximization (EM) algorithm, which is in the SPSS Missing Value Anal-
ysis module [55]. The EM algorithm allows for estimates of missing data from available data
via an iterative maximum likely-hood procedure. Thus, we included in the imputation model
for smoking status missing data the following variables: treatment condition, demographics
(sex, age, marital status, and educational level); cigarette dependence (FTCD), and baseline
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depression (assessed through BDI-II). One-hundred-fifty imputed data sets were generated,
and pooled results are reported. Then, binary logistic regression analyses were conducted to
examine abstinence over time (at the end of treatment, at the 3-, 6-, and 12-month follow-
ups). Both unadjusted and adjusted analyses (controlling for age, sex, marital status, educa-
tional level, baseline cigarette dependence assessed with the FTCD, baseline depression scores
on the BDI-II) were conducted.
In order to examine depression-related primary outcome, analyses were also conducted
using intention-to-treat. To handle missing data, we used MI through the EM algorithm of the
SPSS Missing Value Analysis module. We included in the imputation model the following var-
iables: treatment condition, demographics (sex, age, marital status, and educational level); cig-
arette dependence (FTCD), smoking status, and baseline depression (assessed through
BDI-II). Then, we conducted a Multilevel Analysis (MLM) [56] to examine whether smoking
status was related to depressive symptoms at each time point assessment. In this analysis, we
included the treatment condition, cigarette dependence (FTCD), sex, and history of depression
treatment.
Secondary-related analyses were conducted with those participants with complete data at
each point assessment. To analyze longitudinally cigarette consumption, in terms of mean self-
reported cigarettes per day, for those who were smoking at the 12-month follow-up, we a used
repeated measures analysis of variance (ANOVA). A 2 (SCBSCT vs. SCBSCT-BA) × 5
(repeated measures factor: number of cigarettes per day at baseline, at post-treatment, and at
the 3-, 6-, and 12-month follow-ups) approach was used. We used the Greenhouse–Geisser F
(FGG) to correct for the absence of sphericity [57]. Post hoc analyses were performed with the
Bonferroni test.
Mediation analyses were performed with PROCCESS macro for SPSS [58], in order to
examine whether the number of sessions attended by participants was a mediator between
treatment condition (SCBSCT-BA vs. SCBSCT) and smoking outcomes (abstainer vs. smoker).
We conducted four models testing this relationship at the end of treatment, and at 3-, 6-, and
12-months follow-ups. Bias-corrected bootstrapping (with 20,000 resamples) was used for
assessing indirect effects [59].
SPSS version 24 was used for statistical analysis. The value of the significance level was
set at .05.
Results
Baseline participant characteristics
Table 1 shows demographics, smoking-related and depression-related variables at baseline. No
significant differences were found between groups. Nearly 60% of the sample smoked more
than 20 cigarettes per day, 42.5% were nicotine dependent according to the FTCD (score� 6),
and the average baseline CO was 18.6 ppm (SD = 8.6). Regarding depression-related character-
istics, of the total sample, more than 40% had history of treatment for depression; nearly 18%
received current treatment for depression. Baseline scores on the BDI-II ranged from 0 to 53,
and the mean score was 10.5 (SD = 9.1).
Retention, compliance, and treatment satisfaction
Of the total randomized participants, four assigned to SCBSCT-BA (3.6%), and five to
SCBSCT (4.5%) did not attend the group sessions. A total of 10 out of the 56 participants
assigned to the WL condition did not attended the post-assessment session (17.8%). Of those
participants who attended at least the first treatment session, 95 out of 106 (89.6%) participants
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of the SCBSCT-BA attended the end of treatment session (session 8), whereas 79 out of 104
participants of the SCBSCT did so (75.9%).
Regarding session attendance, 80.9% of the participants in SCBSCT-BA completed at least
6 group sessions, while in SCBSCT, 67.9% of the participants did so, χ2 = 4.87, p = .02. Statisti-
cal group differences were observed when examining the average session attendance (M = 6.7,
SD = 2.03 for CBSCT-BA vs. M = 5.9, SD = 2.41 for CBSCT; t = 2.71, p = .007).
When examining participant’s satisfaction with smoking cessation treatment, they showed
high scores according to CSQ-8, with the 94.7% of the participants in SCBSCT-BA condition,
and 87.3% in SCBSCT reporting to be highly satisfied. No significant differences were found
between both active groups (χ2 = 4.09, p = .13).
Primary smoking outcomes
Biochemically verified 7-days point prevalence abstinence rate for the WL control group was
5.4% after the period of 3-months established. Significant differences were found among active
conditions at the End of Treatment and the WL control group (64.7% SCBSCT-BA vs. 5.4%
WL, p = .001; 45.9% SCBSCT vs. 5.4% WL, p = .001). When comparing both active groups, sig-
nificant differences were also found at the end of treatment (Table 2). Concretely, 71 partici-
pants of the SCBSCT-BA condition (64.7%) and 50 participants of the SCBSCT condition
Table 1. Baseline sociodemographic, smoking-related variables and depression-related variables by trial condition.
SCBSCT-BA
(n = 110)
SCBSCT
(n = 109)
WL
(n = 56)
Mean/n
(SD/%)
Mean/n
(SD/%)
Mean/n
(SD/%)
Age (years) 45.24 (11.2) 44.61 (10.7) 47.07 (10.6)
Gender
Female 67 (60.9) 69 (63.3) 33 (58.9)
Marital status
Married/living with a partner 52 (47.3) 59 (54.1) 29 (51.8)
Single 36 (32.7) 32 (29.4) 14 (25.0)
Divorced/separated/widowed 22 (20.0) 18 (16.5) 13 (23.2)
Education
< HS diploma 19 (17.3) 26 (23.9) 14 (25.0)
HS diploma or GED 42 (38.2) 41 (37.6) 22 (39.3)
College or technical school 49 (44.5) 42 (38.5) 20 (35.7)
Current work situation
Working (yes) 65 (59.1) 63 (57.8) 34 (60.7)
Cigarettes smoked per day 18.85 (7.3) 19.33 (7.4) 19.03 (7.2)
Nicotine content (mg) 0.75 (0.1) 0.74 (0.1) 0.72 (0.2)
Age began daily smoking 18.03 (3.2) 18.31 (3.7) 18.36 (3.6)
Years smoking 26.75 (11.2) 25.24 (11.6) 27.88 (11.3)
Baseline Carbon Monoxide (ppm) 19.22 (8.7) 18.50 (7.2) 17.66 (7.6)
FTCD 4.59 (2.1) 4.95 (2.2) 4.85 (2.1)
Past Depression Treatment (yes) 44 (40.0) 52 (47.7) 23 (41.1)
Current Depression Treatment (yes) 19 (17.3) 20 (18.3) 10 (17.9)
BDI-II 10.27 (8.4) 10.73 (9.6) 10.86 (9.7)
Abbreviations: SCBST-BA = Standard cognitive-behavioral smoking cessation treatment plus BA; SCBST = Standard cognitive-behavioral smoking cessation treatment;
WL = wait list; HS = high school; GED = general education diploma; FTCD = Fagerstro¨m Test for Cigarette Dependence; BDI-II; Beck Depression Inventory.
https://doi.org/10.1371/journal.pone.0214252.t001
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(45.9%) reported 7-days point prevalence abstinence. At 3-, 6, and 12 months follow-ups sig-
nificant differences were also found, with participants randomized to the SCBSCT-BA condi-
tion achieving significant higher 7-days point prevalence abstinence rates than those of the
SCBSCT condition. We also found that at 3-, 6-, and 12-months follow-ups, the rates of miss-
ing data were statistically significant higher for those participants randomized to the SCBSCT
condition, comparing to those of the SCBSCT-BA condition. No significant differences were
found in the category of smokers among treatment conditions.
We performed MI analysis to handle missing data of the primary outcome (biochemically
confirmed 7-days point prevalence abstinence). Then, we run the binary logistic regression
analysis (Table 3), using both unadjusted and adjusted analysis. At the end of treatment, both
adjusted and unadjusted ORs were statistically greater for the SCBSCT-BA condition. At the
3-months follow-up the OR was statistically greater for the SCBSCT-BA, but when adjusted by
covariates did not reach the significance. At 6-, and 12-month follow-ups both abstinence ORs
and AORs were greater but statistically nonsignificant for CBSCT-BA.
Primary depression outcomes
Regarding depression symptoms, no significant differences were found at baseline between the
three groups, F(2, 272) = 0.153, p = .82. At post-treatment, there was a statistically significant
group difference as determined by one-way ANOVA, F(2, 217) = 3.224, p = .04. A Bonferroni
Table 2. Biochemically confirmed abstinence rates, smoking rates and missing data rates by treatment condition (N = 219).
Abstinence Ratesa Smoking rates Missing data rates
SCBSCT-BA
n (%)
SCBSCT
n (%)
SCBSCT-BA
n (%)
SCBSCT
n (%)
SCBSCT-BA
n (%)
SCBSCT
n (%)
χ2 Cramer,s V
EOT 71 (64.5)
�
50 (45.9)
�
25 (22.7) 37 (33.9) 14 (12.7) 22 (20.2) 7.741 .188
3-month follow-up 42 (38.2)
�
25 (22.9)
�
45 (40.9) 45 (41.3) 23 (20.9)
�
39 (35.8)
�
8.438 .189
6-month follow-up 33 (30.0)
�
20 (18.3)
�
48 (43.6) 42 (38.5) 29 (26.4)
�
47 (43.1)
�
7.847 .189
12-month follow-up 33 (30.0)
�
20 (18.3)
�
43 (39.1) 34 (31.2) 34 (30.9)
�
55 (50.5)
�
9.191 .205
Abbreviations: EOT = End of Treatment; SCBST-BA = Standard cognitive-behavioral smoking cessation treatment plus BA; SCBST = Standard cognitive-behavioral
smoking cessation treatment
Note: p value corrected by Bonferroni method
a Abstinence rates = biochemically verified 7-days point prevalence abstinence
�
p� 0.01
https://doi.org/10.1371/journal.pone.0214252.t002
Table 3. Regression analysis biochemically confirmed by treatment condition usingMultiple Imputation.
Abstinence Measures ORa (95% Cl) p AORb (95% Cl) p
SCBSCT-BA vs. SCBSCT SCBSCT-BA vs. SCBSCT
EOTc 2.15 (1.1, 4.0) 0.012 2.0 (1.0, 3.8) 0.031
3-month follow-up 1.87 (1.0, 3.3) 0.045 1.71 (0.8, 3.2) 0.081
6-month follow-up 1.46 (0.7, 2.7) 0.273 1.36 (0.7, 2.6) 0.373
12-month follow-up 1.40 (0.7, 2.7) 0.302 1.41 (0.7, 2.4) 0.310
Note: Abstinence = biochemically verified 7-days point prevalence abstinence (coded as: smoker = 0, abstinent = 1)
aOR = Unadjusted odds ratios
bAOR = Adjusted odds ratios based on binary logistic regression analysis (sex, age, marital status, educational level, cigarette dependence assessed by FTCD, baseline
depressive symptoms scores measured by BDI-II).
cEOT = End of Treatment
https://doi.org/10.1371/journal.pone.0214252.t003
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post hoc test revealed that the SCBSCT-BA (p = .04) and SCBSCT (p = .04) groups reported
significantly lower depressive symptoms than the WL group at the post assessment session. No
significant differences were found at the end of treatment between the active groups (t = .655,
p = .51).
In order to examine the effect of time-varying abstinence on depressive symptoms, a MLM
was conducted with the imputed data. Treatment condition, cigarette dependence, sex, and
past depression treatment were included as covariates in the model, as they could be also
related to depressive symptoms. Results showed that abstinence (vs. smoking) at each point
time assessment was related to a reduction in depressive symptoms (Table 4).
Depressive symptoms means assessed through the BDI-II at each point time (baseline, end
of treatment, 3-, 6- and 12-months follow-up) by smoking status (smoker vs. abstainer) of
those participants with complete data are reported in Fig 2.
Secondary outcomes
We conducted a repeated-measures ANOVA to examine whether cigarette consumption
decreased from baseline to each follow-up point in each treatment condition in the subsample
of participants with complete data and that informed to smoke at the 12-month follow-up
(n = 77). Results showed that participants reduced the number of cigarettes smoked per day
across time, FGG (3.44, 2962.65) = 106.549, p = .001, ηp
2 = 0.587. In addition, data showed sig-
nificant differences between treatment conditions favoring SCBSCT-BA, as participants of this
group smoked significantly fewer cigarettes per day compared to SCBSCT, F(1, 76) = 7.385, p
= .008, ηp
2 = 0.090).
When examining effect sizes of depressive symptoms reduction from baseline to the 12-
month follow up of those participants who provided data in each treatment condition, we
found a small to medium effect size for SCBSCT-BA (d = 0.39) and a small effect for SCBSCT
(d = 0.16). In addition, we also examined behavioral activation (BADS) and environmental
reward (EROS) change from baseline to end-of treatment (Table 5), finding a higher effect size
for both variables in the SCBSCT-BA condition.
Due to we found differences in sessions attendance between conditions, we examined
whether the number of sessions attended by participants was a mediator between treatment
condition (SCBSCT-BA vs. SCBSCT) and smoking 7-days PPA at the end of treatment, and at
3-, 6-, and 12-months follow-ups. These analyses were conducted based on those participants
with complete data (Fig 3). Mediation analyses were performed including as covariates gender,
age, marital status, education, cigarette dependence (FTCD), and baseline depression (BDI-II).
Results of these analysis showed that the indirect effect of the treatment condition through the
Table 4. MLM predicting BDI-II scores at end of treatment, and 3-, 6-, and 12- month follow-ups (n = 210).
Parameter B S.E. 95% C.I. p
Fixed effects
Intercept 8.12 1.07 (6.02, 10.22) 0.001
Past depression treatment (vs. none) 3.65 0.87 (1.93, 5.37) 0.001
Male (vs. Female) 0.41 0.89 (-1.32, 2.16) 0.468
Cigarette dependent (vs. non-dependent) 2.54 0.97 (0.49, 4.43) 0.021
SCBSCT-BA (vs. SCBSCT) -0.03 0.86 (-1.68, 1.69) 0.970
Time-varying Smoking Status
Abstinent (vs. smoker) -3.98 0.78 (-2.43, -5.52) 0.001
Variance components
In time-varying smoking abstinence 1.89 2.87 (0.09, 36.91) 0.509
https://doi.org/10.1371/journal.pone.0214252.t004
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number of sessions attended by participants was significant at the end of treatment (point esti-
mates = 0.194; SE = 0.117; BC 95% CI [0.031, 0.484]), and at 3-months follow-up (point esti-
mates = 0.155; SE = 0.127; BC 95% CI [0.003, 0.486]), while the direct effect was not
significant. The indirect effect did not reach statistically significance at 6-months (point esti-
mates = 0.108; SE = 0.123; BC 95% CI [-0.015, 0.447]), and at 12- months follow-up (point esti-
mates = 0.104; SE = 0.127; BC 95% CI [-0.023, 0.448])
Discussion
This randomized clinical trial was designed to evaluate the efficacy of SCBSCT-BA compared
to SCBSCT, and a WL control group both in smoking cessation and depressive symptom out-
comes. Results indicated that there were significant overall differences across the three condi-
tions at the end of treatment. Confirming our first hypothesis, individuals randomized to the
two active conditions achieved significantly higher abstinence rates and reported fewer depres-
sive symptoms at the end of treatment than those randomized to the WL condition.
When examining our second hypothesis, we found greater abstinence rates for SCBT-BA
when comparing to the active comparator group (SCBSCT) at the end of treatment, and at 3-,
6-, and 12-months follow-up. Nevertheless, when examining regression analysis results, ORs
were only statistically significant greater for SCBT-BA condition at the end of treatment and at
the 3-month follow-up. Additionally, when analyses were adjusted by covariates, the AORs for
SCBT-BA condition were significantly greater only at the end of treatment. Therefore, we only
can partially confirm this hypothesis.
Another relevant smoking-related outcome was that the participants who smoked at the
12-month follow-up reported smoking fewer cigarettes per day than at baseline assessment.
Although this occurred in both active conditions, SCBSCT-BA participants reported a greater
Fig 2. Depressive symptoms by smoking status at the end of treatment, 3-, 6-, and 12-months follow-ups (n = 210). Note. BDI-II: Beck
Depression Inventory–Second edition. Included participants were those who attended at least the first treatment session.
https://doi.org/10.1371/journal.pone.0214252.g002
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reduction of cigarette consumption when compared to the SCBSCT condition. A plausible
explanation is that due to the higher percentage of abstainers in the SCBSCT-BA condition,
the rate of participants who relapsed (vs. those who did not stop smoking at the end of treat-
ment) is higher than in the SCBSCT condition. As a result, these participants could have the
benefit of the abstinence period, as it has been shown that longer periods of abstinence are
associated with greater perceptions of control over smoking behavior, which could translate to
reducing the likelihood of re-establishing previous cigarette consumption [60]. Moreover, it is
also possible that the participants of the SCBSCT-BA condition would have the benefit of strat-
egies addressing positive rewarding activity alternatives to smoking and, consequently, dimin-
ished their cigarette consumption.
Overall, smoking-related results suggest that the BA treatment approach helps smokers to
achieve abstinence, and to reduce smoking heaviness (in terms of reduction of the mean num-
ber of cigarettes smoked per day) among those who relapsed or continued to smoke after treat-
ment. Thus, the potential benefit of adding BA to a smoking cessation treatment found in
previous pilot studies was confirmed [30,31]. As suggested Mckay [61], to address not only
aspects directly related to substance use, but also to focus on making abstinence more reward-
ing, engaging in new hobbies or retaking older ones, making a positive use of leisure time, and
performing other activities that grant a sense of meaning to one’s life can make it more likely
for participants to reduce their substance use. In addition, due to BA focuses on strategies tar-
geting behaviors in response to negative emotional states and distress [15], participants in the
SCBSCT-BA group could benefit from learning coping skills other than smoking when they
experience internal negative states.
Table 5. Mean, standard deviations, and effect sizes for depressive symptoms, behavioral activation, and environmental reward from baseline to the end of treat-
ment and at the 3-, 6-, and 12-month follow-ups.
SCBSCT-BA SCBSCT
Mean SD Cohen’s dab Mean SD Cohen’s dab
BDI-II
Pretreatment 10.27 8.41 — 10.73 9.69 —
End of treatment 8.02 6.80 0.29 7.32 7.37 0.37
3-month follow-up 7.78 9.16 0.28 6.77 9.03 0.40
6-month follow-up 6.34 6.08 0.52 9.95 10.23 0.06
12-month follow-up 7.05 7.98 0.39 8.96 10.99 0.16
EROS
Pretreatment 27.67 4.40 — 27.69 4.93 —
End of treatment 29.50 4.35 0.41 29.11 5.08 0.28
3-month follow-up 29.92 5.14 0.47 28.83 4.65 0.24
6-month follow-up 30.34 4.70 0.58 27.77 5.08 0.02
12-month follow-up 30.48 4.91 0.60 28.55 5.54 0.16
BADS
Pretreatment 104.58 20.77 — 102.00 25.50 —
End of treatment 108.80 20.92 0.20 106.29 24.50 0.17
3-month follow-up 107.63 24.36 0.13 103.71 24.67 0.07
6-month follow-up 109.14 22.89 0.21 101.77 25.09 0.01
12-month follow-up 110.01 23.65 0.24 102.42 28.43 0.01
Note. BDI-II: Beck Depression Inventory–Second edition; EROS = Environmental Reward Observation Scale; BADS = Behavioral Activation Depression Scale
aThe effect size is the comparison of means at each time point with baseline data.
bEach data is based on complete data of participants.
https://doi.org/10.1371/journal.pone.0214252.t005
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Regarding our third hypothesis, we expected a greater reduction of depressive symptoms in
the SCBSCT-BA group, based on previous research [25,30]. When examining depressive
symptoms change from baseline to each follow-up assessment in both treatment conditions,
results showed a higher effect size of such change in the SCBSCT-BA condition. Nevertheless,
multilevel analysis revealed that treatment condition did not significantly predict depressive
symptoms, but instead that time varying-abstinence was related to a reduction in depressive
symptomatology at each time point assessment. This finding is in line with previous research
that found an association between smoking abstinence and depressive symptom reduction
[62–64]. In fact, it has been shown that quitting smoking is associated with a decrease in
depressive symptoms, and also with a reduction in anxiety, stress levels, and an improvement
in quality of life in people with and without psychiatric disorders [65].
These findings could indicate that the mechanism through which BA increases the likeli-
hood of quitting is not through its impact on depression. In previous literature on mood man-
agement interventions for depressed smokers, a similar pattern has been found. Concretely,
mood-focused interventions have been shown to increase efficacy in terms of smoking absti-
nence, but not in reducing depression [66]. A possible explanation of this result could be that
participants may have engaged in activities that are incompatible with smoking, or activities
not previously associated with tobacco use, which are not necessarily related to depression. In
fact, there is evidence showing that increased engagement in substitute reinforcers (alternative
activities to smoking), and decreased engagement in complementary reinforcers (activities
that increase the reinforcing value of tobacco) are associated with smoking abstinence [67,68].
More research is needed to clarify the mechanism through which BA components impact on
smoking outcomes.
Fig 3. Mediation model for treatment condition, number of sessions attended and 7-days point prevalence abstinence. Direct and indirect effects at the end of
treatment, and at 3-, 6-, and 12-months follow-ups.
https://doi.org/10.1371/journal.pone.0214252.g003
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Regarding retention data, we found that participants in the SCBSCT-BA group attended
significantly more sessions and follow-ups than those in the SCBSCT group. Mediation analy-
sis showed that the number of sessions attended by participants mediated in the relation
between treatment condition and abstinence outcomes at the end of treatment and at
3-months follow-up, revealing that SCBSCT-BA was a predictor of session attendance and,
through this relation, a predictor of abstinence outcomes. As no differences regarding treat-
ment satisfaction were found between the two groups, this may be due to the fact that this
treatment approach targets a broad range of smoking and mood-related aspects that provides
participants with higher motivation to attend sessions. Additionally, the BA approach may
have the capacity to retain participants in treatment, especially of those with higher risk of
dropout (i.e., participants with depressive symptomatology or those with lower motivation to
quit). Further research is needed to investigate these hypotheses, and also the predictors of
treatment adherence and their relation to smoking and depression outcomes [69].
Our study has several limitations that should be mentioned. Firstly, missing data through-
out the follow-up period could have affected the accuracy of results of the present study. Nev-
ertheless, this is a frequent phenomenon in clinical trials addressing health-related outcomes
such as smoking cessation [70]. In order to overcome this limitation, we used an analytic
approach (Multiple Imputation) that has been recognized as a useful way to handle missing
data and provide reliable results [53]. Using MI analyses, the AORs, although greater for the
SCBSCT-BA condition, did not reach statistical significance at the 3-, 6-, and 12-month fol-
low-ups. Participants attrition rates, and sample size may have influenced this result, so more
research is needed to confirm long-term effects of BA. Secondly, the use of only two therapists
delivering the treatment conditions could have introduced some biases. Nevertheless, both
therapists had similar experience in smoking cessation treatment and were supervised during
the study by two clinical psychologists. In previous studies where therapist effect was analyzed,
no differences were found between them [2]. Thirdly, despite that both treatments were man-
ualized and included the specific activities carried out session-by-session, the lack of treatment
fidelity coding could be an important limitation. Treatment fidelity/integrity would allow a
more clear interpretation of the obtained results [71], and consequently, future research should
assess and verify the extent to which intervention content is delivered according to treatment
manual specifications [72]. Fourthly, the results obtained may be not generalizable to smokers
in the general population, as participants in this study enrolled voluntarily in a smoking cessa-
tion treatment, which implies a motivation to quit. Finally, the use of self-report question-
naires implies the typical limitations of all self-report assessment instruments (i.e., social
desirability bias). However, we employed commonly used questionnaires that have shown
their reliability and validity.
Despite these limitations, this work has strengths that deserve be highlighted. To date, this
is the largest trial in terms of sample size to address the effects of BA integrated into a cogni-
tive-behavioral smoking cessation treatment. In fact, abstinence rates at 6-, and 12-months fol-
low-ups were of 30%, for the BA condition. Such rates are considerably high, as previous
research showed that abstinence rates of smokers receiving pharmacotherapy at 6-, and
12-months follow-ups are between 14.5 and 28% [73]. In addition, we included two control
conditions, one active group, which allows determine whether the BA approach was superior
to a standard smoking cessation treatment; and one wait-list group, which allows to examine
whether it was superior to the passage of time in which other variables, such as, for example,
motivation or readiness to quit, could be acting. Another marked strength of this work is that
we assessed study variables since the end of treatment to the 3-, 6-, and 12-month follow-ups
in both active groups, which provided the opportunity to evaluate long-term treatment effects
on abstinence rates and depressive symptoms. Moreover, SCBSCT-BA, which was delivered
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time-matched with the standard condition, increased abstinence rates of the standard condi-
tion. This suggests the potential cost-effectiveness of this approach. Finally, these results show
that participants in general could benefit from a BA treatment approach that has been proven
to be a strategy that promotes well-being among nonclinical populations [26].
In summary, the findings of the present study have several significant clinical implications
derived from the relevance of depressive symptoms, regardless of their severity, and the rein-
forcement variables implicated in the smoking cessation process. Our results suggest that add-
ing BA components to a cognitive behavioral treatment for quitting smoking implies greater
abstinence rates in participants with a wide range of depressive symptoms, and also that smok-
ing abstinence is related to a significant reduction of depressive symptoms. Therefore, the
present findings support the benefit of BA as a component suitable for being integrated into
smoking cessation treatments.
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